HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Comella, C. L. Articles by Janko, K. Search for Related Content PubMed PubMed Citation Articles by Comella, C. L. Articles by Janko, K.

Nocturnal activity with nighttime pergolide in Parkinson disease: A controlled study using actigraphy

From the Departments of Neurological Sciences (Dr. Comella, K. Janko) and Nursing (Dr. Morrissey), Rush University Medical Center, Chicago, IL.

Address correspondence and reprint requests to Dr Comella, Department of Neurologic Sciences, Rush University Medical Center, 1725 W. Harrison, Chicago, IL 60612; e-mail: ccomella{at}rush.edu

Pergolide is a dopamine agonist that improves Parkinson disease but is associated with dose-dependent sleepiness. This study evaluates the effect of a nighttime dose of 1 mg of pergolide on actigraphic measures of sleep using a randomized, double-blind, placebo-controlled study design. The pergolide group (n = 10) worsened in actigraphic measures of sleep efficiency and sleep fragmentation vs the placebo group (n = 12). Side effects were more frequent in the pergolide group.

Supported by an unrestricted research grant from Elan Pharmaceuticals. The authors are fully responsible for the conduct of the study, data collection, analyses, and interpretation. The authors own the data set and had the right to publish all data.

Received October 4, 2004. Accepted in final form January 7, 2005.